Results 201 to 210 of about 38,393 (221)

Thiazolidinediones in dermatology

International Journal of Dermatology, 2007
AbstractThiazolidinediones, also known as glitazones, represent a relatively new class of medication used for glycemic control in patients with type II diabetes mellitus. These drugs interact with the peroxisome proliferator‐activated receptor γ, a member of the nuclear receptor superfamily, which in turn heterodimerizes with retinoid X receptors to ...
openaire   +2 more sources

Rosiglitazone, thiazolidinediones and atherosclerosis

Atherosclerosis, 2010
Thiazolidinediones (TZDs) are extensively used in the treatent of type 2 diabetes since this condition is characterized by nsulin resistance and they sensitize patients to the action of nsulin largely through the suppression of hepatic glucose prouction and the suppression of lipolysis at the adipose tissue evel [1].
Paresh, Dandona, Ajay, Chaudhuri, Husam, Ghanim   +2 more
openaire   +2 more sources

Hepatotoxicity of thiazolidinediones

Expert Opinion on Drug Safety, 2003
Thiazolidinediones are insulin sensitisers now widely used for the treatment of Type 2 diabetes mellitus. The initial marketed drug in this class, troglitazone, was removed from the market worldwide after approximately 3 years of use due to rare but severe hepatotoxicity, which sometimes resulted in liver failure leading to the need for liver ...
openaire   +2 more sources

Thiazolidinediones

Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...
Kam L. Capoccia, Peggy Soule Odegard
openaire   +1 more source

Hepatotoxicity of the thiazolidinediones

Clinics in Liver Disease, 2003
Troglitazone, the first of the thiazolidinediones, caused severe hepatotoxicity including liver failure in several patients. It appears, however, that the thiazolidinediones as a class are not as hepatotoxic as troglitazone. Comparative data at comparable dates of usage indicate that pioglitazone and rosiglitazone are not significant hepatotoxins. This
Keith G, Tolman, Jane, Chandramouli
openaire   +2 more sources

Thiazolidinediones – some recent developments

Expert Opinion on Investigational Drugs, 2003
The role of thiazolidinediones (currently rosiglitazone and pioglitazone) in the treatment of Type 2 diabetes is firmly established. The mechanism of action involves binding to the peroxisome proliferator-activated receptor-gamma, a transcription factor that regulates the expression of specific genes especially in fat cells but also other cell types ...
openaire   +2 more sources

Thiazolidinediones and cardiovascular disease

Current Atherosclerosis Reports, 2005
Thiazolidinediones hold promise for reducing cardiovascular events and human atherosclerosis. Similar to statins and angiotensin-converting enzyme inhibitors, peroxisome proliferator activated receptor gamma (PPARgamma) exerts anti-inflammatory and antiatherosclerotic actions in the vessel wall.
Robert, Chilton, Elaine, Chiquette
openaire   +2 more sources

Pharmacogenetics of Thiazolidinedione Therapy

Pharmacogenomics, 2007
The thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor-gamma agonists and have glucose-lowering, insulin-sensitizing and anti-inflammatory effects. TZDs are approved for the treatment of Type 2 diabetes, and have been studied as a diabetes-prevention strategy.
openaire   +2 more sources

Pharmacokinetic Interactions with Thiazolidinediones

Clinical Pharmacokinetics, 2007
Type 2 diabetes mellitus is a complex disease combining defects in insulin secretion and insulin action. New compounds called thiazolidinediones or glitazones have been developed for reducing insulin resistance. After the withdrawal of troglitazone because of liver toxicity, two compounds are currently used in clinical practice, rosiglitazone and ...
openaire   +2 more sources

Thiazolidinediones

Nihon rinsho. Japanese journal of clinical medicine, 2011
Tsukasa, Nakamura, Yoshihiko, Ueda
openaire   +3 more sources